Bovine Mastitis Market - By Product, By Type, By Route of Administration, By End Use & Growth Forecast, 2025 – 2034

Bovine Mastitis Market Size

The global bovine mastitis market was estimated at USD 2 billion in 2024. The market is expected to grow from USD 2.2 billion in 2025 to USD 3.7 billion in 2034, at a CAGR of 6.3%. The increasing prevalence of bovine mastitis, heightened awareness pertaining to animal health and welfare, and the growing demand for dairy products are driving the need for innovative diagnostic and treatment solutions.
 

For instance, according to the BMC Veterinary Research article, among the 529 lactating cows selected randomly from 95 herds, the prevalence of mastitis at herd-level was 74.7%. The corresponding cow-level prevalence was 62.6%, of which 59.2 and 3.4% were sub-clinical and clinical mastitis cases, respectively. This shows the importance of developing advanced solutions to ensure the health and productivity of dairy cows, which are essential for meeting global dairy demands.
 

Moreover, new and improved diagnostic technologies are accelerating the early detection of mastitis. Established veterinary companies are investing in developing novel therapeutics, including vaccines, antibiotics, and natural remedies, to combat drug resistance and improve treatment outcomes. The industry is also benefiting from government initiatives and research directed towards increasing livestock health and productivity.
 

Bovine mastitis is the inflammation of the udder tissue in dairy cows, caused by bacterial infection. The bovine mastitis industry encompasses diagnostics, therapeutics, and preventive solutions that help improve animal health and minimize production losses.
 

Bovine Mastitis Market Trends

• The bovine mastitis industry is expanding due to improvements in mastitis diagnostics, rising cases of mastitis occurrence, and growing concern about animal welfare. Mastitis is still considered one of the most common diseases in dairy cows, affecting 25-30% of cows in any given year.
   
• According to the National Institutes of Health (NIH), the total annual economic losses to U.S. dairy farmers due to mastitis are estimated to be between USD 400 and USD 500 million, which equates to approximately USD 23 per cow. This highlights the critical need for better mastitis management to minimize the economic burden.
   
• Also, partnerships and collaborations between pharmaceutical and biotech companies drive the market growth. For example, Amicogen has partnered with Lysando to address the challenge of mastitis in dairy cows caused by multi-resistant bacteria. This collaboration leverages Amicogen’s industrial enzyme expertise and Lysando’s antimicrobial Artilysin technology. This reflects a growing trend towards innovative, non-antibiotic treatments to enhance animal health.
   
• Moreover, advancements in diagnostic technologies have driven the sector in udder infection management. A July 2023 National Library of Medicine article highlights tools like PCR, acute phase protein detection, ELISA, and qPCR, which enhance pathogen detection accuracy and specificity, even at the subspecies level. This enables more effective treatment strategies.
   
• Similarly, in June 2024, IIT Kanpur’s mastitis detection technology transferred to Prompt Equipments which focuses on the cow’s health conditions by speeding up and fine-tuning diagnosis to enable proactive intervention and treatment. This innovation aligns with the trend of advanced diagnostics, enhancing accuracy and herd health in the bovine mastitis market.
   
• The adoption of artificial intelligence alongside digitalized record keeping is transforming precision livestock farming by allowing monitoring and treatment of livestock in real time. Australia’s Clinical Mastitis Decision Support Tool Project, which brings together dairy farmers, industry experts and researchers into a USD 3.5 million project. It offers precise diagnostics to minimize antibiotic therapy, provide tailored solutions, and combines data with Dairy Industry’s DataVat platform for active mastitis control.
   
• Therefore, as dairy farmers comprehend that the health of animals is proportional to the quantity of milk produced, there is an increased focus on proactive management and routine mastitis examinations. Industry players are promoting herd management practices that reduce infection risk and improve milk quality.
   

Bovine Mastitis Market Analysis

Based on the product, the market is segmented into pharmaceutical and diagnostics. The pharmaceutical segment is further bifurcated into antibiotics, vaccines and other pharmaceuticals. The pharmaceutical segment dominated the market with USD 1.39 billion in 2021, USD 1.46 billion in 2022 and USD 1.54 billion in 2023.  
 

• The pharmaceutical segment focuses on developing treatments to combat infections in dairy cattle. This veterinary medicine segment covers antibiotic and anti-inflammatory drug usage and supportive therapy to control clinical and subclinical mastitis.
   
• Penicillin and cephalosporin are the most common antibiotics used in mastitis treatment. Also, innovations in intramammary infusion treatments continue to enhance treatment efficacy.
   
• Further, the availability of advanced drug formulations and novel biologic drugs enhances the market growth. Pharmaceutical industries are also researching combination therapies to increase compliance and eliminate resistance whilst boosting milk safety.
   
• For instance, as per the article ‘The effect of dry cow therapy in combination with common intramammary medications, the dry cow therapy of CMT-positive cows using a combination of tylosin (12 g, IM) and IMM administration of penethamate hydriodide, benethamine penicillin and framycetin sulfate may result in a significant reduction of the rate and severity of acute and chronic mastitis.
   

Based on type, the bovine mastitis market is divided into clinical mastitis, and sub-clinical mastitis. The clinical mastitis segment accounted for a significant market share of 55% in 2024.      
 

• Clinical mastitis is a key segment of this market because of possible milk yield reduction and its visible symptoms. The Canadian Bovine Mastitis Research Network (CBMRN) conducted a study on 41 herds comprising of 458 dairy cows, which revealed that the incidence of clinical mastitis stood at 26.3 per 100 cows. This highlights the importance of diagnosis and treatment of clinical mastitis.
   
• Therefore, the increasing necessity to treat clinical mastitis along with the growing availability of drugs and awareness is accelerating its treatment on a global scale. More dairy farms are now beginning to utilize automated milking as well as clinical mastitis detection systems.
   
• Further, due to growing cases of antimicrobial resistance, there is an increasing demand for non-antibiotic therapies that include probiotics, vaccines, and herbal medicines.
   
• For example, Mastirak Gel, a poly-herbal medicine designed by National Innovation Foundation (NIF) is used to improve udder health, reduce inflammation and minimize antibiotic usage while managing costs. This innovation highlights the potential of herbal medicines in the market.
   

Based on route of administration, the bovine mastitis market is divided into intra-mammary, and systemic. The intra-mammary segment dominated the market with USD 1.2 billion in 2024 and is expected to grow at 6.2% during the analysis period.   
    

• The intra-mammary segment is important in improving infection management at the level of the infected udder tissues. It comprises antibiotics, anti-inflammatory agents and teat sealants.
   
• The teat sealants are also used to avert infections during the dry period mastitis, which is gaining attention in the segment. Automated milking and monitoring systems further enhance treatment precision.
   
• Further, over the past few years, there has been increasing regulatory control concerning the misuse of antibiotics, leading to more innovation in non-antibiotic intramammary therapies, including natural medicine. The emergence of technologies for precision livestock farming is making it easier to monitor cows’ health, facilitating early intervention for mastitis.
   

Based on end use, the bovine mastitis market is divided into veterinary hospitals and clinics, diagnostic laboratories, and other end users. The veterinary hospitals and clinics segment dominated the market in 2024 and is expected to reach 1.9 billion by 2034.   
 

• Veterinary hospitals and clinics play important role in disease diagnosis and treatment, as well as prevention. These facilities have lab-based mastitis diagnostics along with other more advanced imaging and treatment options available at the facility.
   
• Dairy farmers are changing their practices due to increasing knowledge of mastitis prevention and early intervention, which has made them willing to use professional veterinary services. This segment also enhances farmers’ knowledge on milking hygiene, antibiotic treatment, and other routine preventive measures.
   
• Additionally, veterinary hospitals have started using digital health records and monitoring devices on farms to develop specific mastitis control programs, ensuring better dairy herd health outcomes.
   

North America bovine mastitis market held the largest market share of 38.7% in 2024 in the global bovine mastitis industry. The U.S. market was valued at USD 616.5 million in 2021 and USD 648.3 million in 2022 and reached USD 683 million in 2023.
 

• High population of livestock animals drives market growth in the country. As per U.S. Department of Agriculture (USDA), there were 87.2 million head of cattle and calves on the U.S. farms as of January 2024.
   
• The demand for good quality milk has spurred comprehensive dairy farming coupled with sophisticated veterinary services. For instance, the U.S. Department of Agriculture (USDA) reports that in 2022 there was an increase of approximately 34,000 dairy farms in the U.S. This trend has increased the adoption of rapid diagnostics, efficient intramammary antibiotics, and non-antibiotic intramammary therapies.
   
• In efforts to lower the levels of antibiotic resistance, the U.S. employs innovative approaches including the use of vaccines and probiotics. Governmental organizations like FDA supervise the use of antibiotics.
   
• The market is also affected by increased health consciousness and the rising use of farm automation technologies. There is a great concentration of these industries with many offering a wide variety of treatment and prevention measures for dairy farmers in the U.S.  
   

Europe bovine mastitis market accounted for USD 573.3 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Advancements in veterinary medicine with frequent introduction and approval of novel pharmaceuticals will boost the market in the Europe region.
   
• Also, the presence of highly equipped veterinary clinics and hospitals in Germany, UK, and France boosts the Europe bovine mastitis industry.
   

• The German market for bovine mastitis is influenced by the quality milk production standards. Farmers are proactive, resulting in the widespread use of prior-use teat sealants and probiotics and other natural products.
   
• Further, the German dairy industry has also benefited from the government’s investment into the research of detection and treatment of mastitis diseases. Therefore, increasing Germany’s shift to organic farming for sustainable and green solutions to mastitis difficult will spur the country level market in coming years.  
   

The Asia Pacific bovine mastitis market witnessed substantial growth of 6.6% during the analysis period. China market is poised to witness high growth over the analysis period.
 

• China’s bovine mastitis industry is expanding rapidly due to the increasing dairy consumption and substantial cattle population of the country. The use of modern veterinary services, as well as the overall milking and disease monitoring practices in China is improving.
   
• In China, the available information indicates that bovine mastitis is one of the most devasting diseases among dairy cows, particularly SCM. However, owing to a lack of awareness about the negative impact of mastitis and lack of comprehensive strategy to prevent and control this disease, the incidence of mastitis, especially SCM, has increased continuously on most dairy cow farms in China
   
• Therefore, with usage of modern antibiotics, China needs more regulatory control to further encourage the use of vaccines and herbal supplements, thereby augmenting the market growth.
   

Bovine Mastitis Market Share

The top 5 companies in the bovine mastitis industry account for ~70% of the market share, with Zoetis leading the industry, followed by Boehringer Ingelheim, Merck & Co. Inc., DeLaval, and Elanco. These companies dominate the market through strategic acquisitions, continuous innovation, and expanding product portfolios. These companies offer solutions for mastitis prevention, diagnostics, and treatment.
 

Furthermore, to expand their market presence, key players are actively forming partnerships and collaborations with biotech firms, pharmaceutical companies, and research institutions. Companies such as HIPRA focus on developing vaccines, while DeLaval make diagnostics solutions. To maintain competitive edge, companies are actively investing in research and development.
 

Bovine Mastitis Market Companies

Major players operating in the bovine mastitis industry are:

• Advanced Animal Diagnostics
• Boehringer Ingelheim
• Ceva
• DeLaval
• Elanco
• Heilsaa
• HIPPRA
• ImmuCell Corporation
• Merck & Co
• Norbrook
• Virbac
• Zoetis
   

Boehringer Ingelheim focuses on immune-enhancing mastitis solutions. For example, its Ubrolexin intramammary antibiotic are widely used for mastitis recovery and prevention.
 

Zoetis offers an extensive portfolio of bovine mastitis treatments, including antibiotics and vaccines like Spectramast LC, which targets clinical mastitis during lactation.
 

DeLaval provides innovative milking systems and mastitis management solutions. Its DeLaval VMS milking robots integrate automatic detection of mastitis symptoms, ensuring timely intervention.
 

Bovine Mastitis Industry News

• In September 2022, Boehringer Ingelheim introduced new susceptibility testing criteria for Ubrolexin, aimed at optimizing its effectiveness in treating mastitis in dairy cows. This update enhances precision in targeting mastitis-causing pathogens, promoting improved treatment outcomes and udder health in dairy herds.
   
• In January 2022, DeLaval launched the Evanza cluster, a milking solution designed to improve teat health and reduce mastitis rates in dairy cattle. This innovation aims to enhance milk production efficiency and support bovine mastitis prevention efforts in the dairy industry.
   
• In April 2021, Boehringer Ingelheim expanded its dairy mastitis portfolio by introducing a blue internal teat sealant. This product aims to enhance mastitis prevention and improve udder health by providing an effective barrier against bacterial infections in dairy cows.
   

The bovine mastitis market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Pharmaceutical
  • Antibiotics
  • Vaccines
  • Other pharmaceuticals
• Diagnostics

Market, By Type

• Clinical mastitis
• Sub-clinical mastitis

Market, By Route of Administration

• Intra-mammary
• Systemic

Market, By End Use

• Veterinary hospitals and clinics
• Diagnostic laboratories
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE